Patent US4072746A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4072746A Expired / Lapsed US ⏱️ 0.0 years remaining

3-Amino-5-(pyridinyl)-2(1H)-pyridinones

Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1976-07-21
•
Granted: 1978-02-07
•
Expires: 1996-07-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds useful as cardiotonic agents are 1-R-3-Q-5-PY-2(1H)-pyridinones (I) where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, Q is amino (preferred), lower-alkylamino, di-(lower-alkyl)amino or NHAc, Ac is lower-alkanoyl or lower-carbalkoxy, and PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents. The corresponding compounds where Q is nitro, carbamyl, cyano, halo or hydrogen are useful as intermediates and those where Q is hydrogen or cyano also are useful as cardiotonic agents. Said compounds are prepared: by reacting alpha -PY- beta -(R1R2N)acrolein (II) with malonamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinamide (Ia) and reacting Ia with a reagent capable of converting carbamyl to amino to produce 3-amino-5-PY-2(1H)-pyridinone (Ib); by reacting II or alpha -PY-malonaldehyde (II') with alpha -cyanoacetamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinonitrile (III) and partially hydrolyzing III to produce Ia; and, by heating 1,2-dihydro-2-oxo-5-PY-nicotinic acid (IV) with a mixture of concentrated sulfuric acid and concentrated nitric acid to produce 3-nitro-5-PY-2(1H)-pyridinone (Ic) and then either reducing Ic to produce Ib or first reacting Ic with an alkylating agent to produce 1-R'-3-nitro-5-PY-2(1H)-pyridinone (Id) and reducing Id to produce 1-R'-3-amino-5-PY-2(1H)-pyridinone (Ib) where R' is lower-alkyl or lower-hydroxyalkyl. Other derivatives of I where Q is amino are shown.

Inventors

  • 👤 George Y. Lesher
  • 👤 Chester J. Opalka, Jr.

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 22:58
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/44; C07D213/53; C07D213/36; C07D213/38; C07D213/46; C07D213/48; C07D213/60; C07D213/62; C07D213/63; C07D213/64; C07D213/72; C07D213/73; C07D213/74; C07D213/75; C07D213/78; C07D213/79; C07D213/80; C07D213/81; C07D213/82; C07D213/84; C07D213/85

Claims Analysis

Total Claims: 27
Claim 1
Independent Claim 53 words
A 1-R-3-Q-5-PY-2 (1H)-pyridinone having the formula ##STR4## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is nitro, amino, lower-alkylamino di-(lower-alkyl)amino, or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 2
Dependent Claim 53 words
A 1-R-3-Q-5-PY-2 (1H)-pyridinone having the formula ##STR4## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is nitro, amino, lower-alkylamino di-(lower-alkyl)amino, or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 3
Dependent Claim 52 words
A 1-R-3-Q-5-PY-2 (1H)-pyridinone having the formula ##STR5## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is nitro, lower-alkylamino, di-(lower-alkyl)amino, or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 4
Dependent Claim 52 words
A 1-R-3-Q-5-PY-2 (1H)-pyridinone having the formula ##STR5## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is nitro, lower-alkylamino, di-(lower-alkyl)amino, or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 5
Dependent Claim 39 words
A 1-R-3-amino-5-PY-2 (1H)-pyridinone having the formula ##STR6## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents and R is hydrogen, lower-alkyl or lower-hydroxyalkyl, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 6
Dependent Claim 39 words
A 1-R-3-amino-5-PY-2 (1H)-pyridinone having the formula ##STR6## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents and R is hydrogen, lower-alkyl or lower-hydroxyalkyl, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 7
Dependent Claim 10 words
A compound according to claim 2 where Q is nitro.
Claim 8
Dependent Claim 10 words
A compound according to claim 3 where R is hydrogen.
Claim 9
Dependent Claim 10 words
A compound according to claim 3 where R is lower-alkyl.
Claim 10
Dependent Claim 3 words
3-Amino-5-(4-pyridinyl)-2 (1H)-pyridinone .
Claim 11
Dependent Claim 3 words
3-Amino-5-(4-pyridinyl)-2 (1H)-pyridinone .
Claim 12
Dependent Claim 6 words
3-Amino-5-(3-pyridinyl)-2 (1H)-pyridinone according to claim 5.
Claim 13
Dependent Claim 6 words
3-Amino-1-methyl-5-(4-pyridinyl)-2 (1H)-pyridinone according to claim 6.
Claim 14
Dependent Claim 6 words
3-Amino-1-ethyl-5-(4-pyridinyl)-2 (1H)-pyridinone according to claim 6.
Claim 15
Dependent Claim 5 words
N-[1,2-Dihydro-2-oxo-5-(4-pyridinyl)-3-pyridinyl]-acetamide according to claim 2.
Claim 16
Dependent Claim 6 words
Methyl N-[1,2-dihydro-2-oxo-5-(4-pyridinyl)-3-pyridinyl]carbamate according to claim 2.
Claim 17
Dependent Claim 6 words
3-Nitro-5-(4-pyridinyl)-2 (1H)-pyridinone according to claim 4.
Claim 18
Dependent Claim 77 words
A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic 1-R-3-Q-5-PY-2 (1H)-pyridinone having the formula ##STR7## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is amino, lower-alkylamino, di-(lower-alkyl)amino or NHAc where Ac is lower-alkanoyl or loer-carbalkoxy, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 19
Dependent Claim 77 words
A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic 1-R-3-Q-5-PY-2 (1H)-pyridinone having the formula ##STR7## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is amino, lower-alkylamino, di-(lower-alkyl)amino or NHAc where Ac is lower-alkanoyl or loer-carbalkoxy, or pharmaceutically-acceptable acid-addition salt thereof.
Claim 20
Dependent Claim 13 words
A composition according to claim 14 where the active component is 3-amino-5-(4-pyridinyl)-2 (1H)-pyridinone.
Claim 21
Independent Claim 87 words
The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic 1-R-3-Q-5-PY-2 (1H)-pyridinone having the formula ##STR8## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is amino, lower-alkylamino, di-(lower-alkyl) amino or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy, or pharmaceutically acceptable acid-addition salt thereof.
Claim 22
Independent Claim 87 words
The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic 1-R-3-Q-5-PY-2 (1H)-pyridinone having the formula ##STR8## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is amino, lower-alkylamino, di-(lower-alkyl) amino or NHAc where Ac is lower-alkanoyl or lower-carbalkoxy, or pharmaceutically acceptable acid-addition salt thereof.
Claim 23
Dependent Claim 13 words
The method according to claim 16 where the 1-R-3-Q-5-PY-2 (1H)-pyridinone is 3-amino-5-(4-pyridinyl)-2 (1H)-pyridinone.
Claim 24
Dependent Claim 14 words
A compound according to claim 2 where Q is lower-alkylamino and R is hydrogen.
Claim 25
Dependent Claim 6 words
3-Methylamino-5-(4-pyridinyl)-2 (1H)-pyridinone according to claim 18.
Claim 26
Dependent Claim 15 words
A compound according to claim 2 where Q is di-(lower-alkyl) amino and R is hydrogen.
Claim 27
Dependent Claim 6 words
3-Dimethylamino-5-(4-pyridinyl)-2 (1H)-pyridinone according to claim 20.

References Cited (Backward Citations)

US3814771A Cited
US3853896A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-02-06 1981-08-08 1982-02-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-02-06 1985-08-08 1986-02-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-02-06 1989-08-08 1990-02-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag